Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1986 4
1998 1
2000 2
2001 2
2002 2
2003 5
2004 1
2005 1
2006 2
2007 3
2008 3
2009 4
2010 4
2011 3
2012 2
2013 3
2014 1
2015 2
2016 7
2017 3
2018 7
2019 10
2020 11
2021 17
2022 10
2023 6
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Anker SD, et al. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449189 Clinical Trial.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Packer M, et al. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. N Engl J Med. 2020. PMID: 32865377 Free article. Clinical Trial.
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Yasuda S, et al. N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2. N Engl J Med. 2019. PMID: 31475793 Clinical Trial.
Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation.
Kanaoka K, Onoue K, Terasaki S, Nakano T, Nakai M, Sumita Y, Hatakeyama K, Terasaki F, Kawakami R, Iwanaga Y, Miyamoto Y, Saito Y; Japanese Registry of Fulminant Myocarditis Investigators. Kanaoka K, et al. Circulation. 2022 Nov 8;146(19):1425-1433. doi: 10.1161/CIRCULATIONAHA.121.058869. Epub 2022 Sep 27. Circulation. 2022. PMID: 36164974
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Free PMC article. Clinical Trial.
Free Flap Reconstruction of Oncologic Gluteal Defects.
Arikawa M, Akazawa S, Kagaya Y, Kawai A, Miyamoto S. Arikawa M, et al. Ann Plast Surg. 2022 Apr 1;88(4):420-424. doi: 10.1097/SAP.0000000000003027. Ann Plast Surg. 2022. PMID: 34611088
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Verma S, et al. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. Lancet Diabetes Endocrinol. 2022. PMID: 34861154
Serial Optical Coherence Tomography Assessment of Coronary Atherosclerosis and Long-Term Clinical Outcomes.
Yamaji K, Kanenawa K, Morofuji T, Nishikawa R, Imada K, Kohjitani H, Watanabe H, Tazaki J, Taniwaki M, Koga S, Akashi R, Kubo S, Ohya M, Kikuchi T, Ohira H, Numasawa Y, Arikawa M, Iwama M, Kitai T, Kobayashi Y, Shiomi H, Tada T, Yamaji Y, Daidoji H, Ohtani H, Furukawa Y, Kadota K, Toyofuku M, Ando K, Ono K, Kimura T; PREDICTOR investigators. Yamaji K, et al. Among authors: arikawa m. J Am Heart Assoc. 2024 Nov 5;13(21):e034458. doi: 10.1161/JAHA.123.034458. Epub 2024 Oct 22. J Am Heart Assoc. 2024. PMID: 39435729 Free article.
106 results